Next Article in Journal
Erratum: Current and Emerging Biomarkers in Metastatic Colorectal Cancer
Previous Article in Journal
A Primer on the Genetics of Medullary Thyroid Cancer
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Impact of the Gut Microbiome on Immune Checkpoint Inhibitor Efficacy—A Systematic Review

Department of Medical Oncology, Centre Hospitalier Jolimont, 159 rue Ferrer, Haine Saint Paul 7100 Belgium
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(6), 395-403; https://doi.org/10.3747/co.26.5177
Submission received: 5 September 2019 / Revised: 3 October 2019 / Accepted: 9 November 2019 / Published: 1 December 2019

Abstract

Background: Immune checkpoint inhibitors (icis) are increasingly being used in clinical practice, improving outcomes for cancer patients. Preclinical models showed significant interaction between the gut microbiome (gm) and response to icis. However, that interaction remains unclear in clinical practice. Methods: We performed a systematic review in medline to determine (1) whether antibiotics affect ici efficacy, (2) whether baseline gm composition and ici efficacy show any correlations, (3) whether baseline gm composition and emergence of immune-related adverse events (iraes) show any correlations, and (4) whether gm manipulation can alleviate the iraes. Included publications had to be written in English or French and had to describe a quantifiable link between gm composition or its modification and the response to icis or the occurrence of iraes, or both. Results: Of 1451 articles published before December 2018, 13 publications met the inclusion criteria. Five full-text articles and two abstracts highlighted a negative effect of antibiotics on ici efficacy. The composition of the gm was associated with ici efficacy in five full-text articles and one abstract, and with iraes in two full-text articles. In 2 cases, fecal microbiota transplantation was reported to reduce immune colitis. Conclusions: If possible, antibiotics should be avoided before ici treatment because of their negative effect on ici anticancer efficacy. No specific commensal bacterium was associated with ici efficacy, but an intact gm with high bacterial diversity and a good ratio of “responder-associated” bacteria to “non-responder-associated” bacteria seem to be correlated with better patient outcomes. Fecal microbiota transplantation is a promising technique for reducing ici-associated colitis.
Keywords: Antibiotics; cancer immunotherapy; fecal microbiota transplantation; immune checkpoint inhibitors; microbiome Antibiotics; cancer immunotherapy; fecal microbiota transplantation; immune checkpoint inhibitors; microbiome

Share and Cite

MDPI and ACS Style

Pierrard, J.; Seront, E. Impact of the Gut Microbiome on Immune Checkpoint Inhibitor Efficacy—A Systematic Review. Curr. Oncol. 2019, 26, 395-403. https://doi.org/10.3747/co.26.5177

AMA Style

Pierrard J, Seront E. Impact of the Gut Microbiome on Immune Checkpoint Inhibitor Efficacy—A Systematic Review. Current Oncology. 2019; 26(6):395-403. https://doi.org/10.3747/co.26.5177

Chicago/Turabian Style

Pierrard, Julien, and E. Seront. 2019. "Impact of the Gut Microbiome on Immune Checkpoint Inhibitor Efficacy—A Systematic Review" Current Oncology 26, no. 6: 395-403. https://doi.org/10.3747/co.26.5177

APA Style

Pierrard, J., & Seront, E. (2019). Impact of the Gut Microbiome on Immune Checkpoint Inhibitor Efficacy—A Systematic Review. Current Oncology, 26(6), 395-403. https://doi.org/10.3747/co.26.5177

Article Metrics

Back to TopTop